Comparison of gene expression between natural ligand treatment and agonistic antibody treatment in a CD30+ cell line
Ontology highlight
ABSTRACT: CD30 receptor (TNFRSF8) is highly expressed in some types of lymphoma. CD30 is successfully used as a target for antibody-drug conjugate to treat CD30+ lymphoma. The agonistic activity of the anti-CD30 antibody likely contributes to tumor cell killing. However, not all antibodies exhibit agonistic activity. We found that potent agonistic antibodies recognize the N-terminus epitope cluster that is distantly located from the ligand binding site of CD30. This study compared gene expression profiles between CD30 natural ligand and agonistic antibody T104 treatment in a CD30+ ALCL Karpas 299 cell line.
ORGANISM(S): Homo sapiens
PROVIDER: GSE59174 | GEO | 2025/08/10
REPOSITORIES: GEO
ACCESS DATA